Joint inflammation and cytokine inhibition in rheumatoid arthritis

Clinical and Experimental Medicine

Volumn 6, Issue 1, 2006, Pages 13-19

  Christodoulou, C ^a   Choy, E H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti tumour necrosis factor alpha agents; Cytokines; Interleukin 1; Rheumatoid arthritis; Tumour necrosis factor alpha

Indexed keywords

ADALIMUMAB; AMG 714; ATLIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 6; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DYSFUNCTION; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS;

EID: 33645130483     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-006-0088-5     Document Type: Review

References (60)

1. Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39:28-33
2. Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 42:1209-1218
3. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over 5 years. Arthritis Rheum 27:864-872
4. Blass S, Engel JM, Burmester GR (2001) The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and its therapeutic consequences. Z Rheumatol 60:1-16
5. Isler P, Vey E, Zhang JH, Dayer JM (1993) Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Nerve 4:15-23
6. Houssiau PA (1995) Cytokines in rheumatoid arthritis. Clin Rheumatol 14[Suppl 2]:10-13
7. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y (1993) The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TMIP production by synovial cells and endothelial cells. Clin Exp Immunol 94:145-149
8. Choy EH, Panayi GS (2001) Mechanisms of disease: cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916
9. Beutler BA (1999) The role of tumour necrosis factor in health and disease. J Rheumatol 26[Suppl 57]:16-21
10. Zhang Z, Bridges SL Jr (2001) Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 27:335-353
11. Brennan FM, Maini RN, Feldmann M (1998) Role of proinflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 20:133-147
12. Feldmann M, Maini RN (1999) The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology 38[Suppl 2]:3-7
13. Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305-315
14. Dayer JM, Beutler B, Cerami A (1985) A cachectin/tumour necrosis factor alpha stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162:163-168
15. Lader CS, Flanagan AM (1998) Prostaglandin E2, Interleukin-1 alpha, and tumour necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 139:3157-3164
16. Jenkins JK, Hardy KJ, McMurray RW (2002) The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 323:171-180
17. Chu CQ, Field M, Feldmann M et al (1991) Localisation of tumour necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125-1132
18. Neidel J, Schuize M, Lindschau J (1995) Association between degree of bone-erosion and synovial fluid-levels of tumour necrosis factor alpha in the knee joints of patients with rheumatoid arthritis. Inflamm Res 44:217-221
19. Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-alpha antibody with interleukin-1 receptor antagonist. Eur Cytokine Netw 6:225-230
20. Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031
21. Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607
22. Williams RO, Feldmann M, Maini RN (1992) Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784-9788
23. Koch AE, Kunkel SL, Strieter RM (1995) Cytokines in rheumatoid arthritis. J Invest Med 43:28-38
24. Suzuki Y, Tanihara M, Ichikawa Y, Osanai A, Nakagawa M, Ide M, Mizushima Y (1995) Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann Rheum Dis 54:484-490
25. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russel RG (1983) An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306:378-380
26. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI (1990) Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumour necrosis factor-alpha on stromelysin expression. J Biol Chem 265:17238-17245
27. Pettipher ER, Higgs GA, Henderson B (1986) Interleukin I induces leucocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A 83:8749-8753
28. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Rα. Arthritis Rheum 39:797-809
29. Sims JE, March CJ, Cosman D et al (1988) cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241:585-589
30. McMahan CJ, Slack JL, Mosley B et al (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10:2821-2832
31. Sims JE, Gayle MA, Slack JL et al (1993) Interleukin 1 signalling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A 90:6155-6159
32. Colotta F, Re F, Muzio M et al (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261:472-475
33. Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. FASEB J 8:1314-1325
34. Van Snick J (1990) Interleukin-6: an overview. Annu Rev Immunol 8:253-278
35. Houssiau FA, Devogelaer J-P, Van Damme J, Nagant de Deuxchaisnes C, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784-788
36. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G (1992) Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19:22-25
37. Kotake S, Sato K, Kim KJ et al (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88-95
38. Watson J, Crilly A, Madhok R, Capell H, Sturrock R (1992) IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs. Biochem Soc Trans 20:138S
39. Grabstein KH, Eisenman J, Shanebeck K et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965-968
40. Waldmann TA, Tagaya Y (1999) The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17:19-49
41. Kotake S, Schumacher HR Jr, Yarboro CH et al (1997) In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc Assoc Am Physicians 109:286-301
42. Mohler KM, Torrance DS, Smith CA et al (1993) Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561
43. Moreland LW, Schiff MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis: a randomised controlled trial. Ann Intern Med 130:478-486
44. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147
45. Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593
46. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumour necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259
47. Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110
48. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
49. Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939
50. Lipsky PE, van der Heijde DMFM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594-1602
51. Weinblatt ME, Keystone EC, Frust DE et al (2003) Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35-45
52. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AMM (2002) Long-term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61:311-318
53. Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196-2204
54. Cohen S, Hurd E, Cush J et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist (IL-1Ra) in combination with methotrexate. Arthritis Rheum 46:614-624
55. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, IL-1Ra Arthritis Study Group (1996) Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39:1092-1101
56. Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404-410
57. Nishimoto N, Yoshizaki K, Miyasaka N et al (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761-1769
58. Maini RN (2004) Anti-IL6 receptor therapy: rationale and early results in rheumatoid arthritis. Ann Rheum Dis 63[Suppl 1]:25-26, Abstract
59. Baslund B, Tvede N, Danneskiold-Samsoe B et al (2005) Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 52:2686-2692
60. McInnes I, Martin R, Zimmerman-Gorska I et al (2004) Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): Results from a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 50[Suppl 9]:S241